https://doi.org/10.1200/jco.2016.72.0946
A
Antonia Perelló
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
118
Papers
2.8K
Citations
25
h-index
34
i10-index
Antonia Perelló is an academic researcher from Hospital Universitario Son Espases. The author has contributed to research in topics: Advanced Breast Cancer Therapies & HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies. The author has an h-index of 25, co-authored 101 publications.
ORCID: 0000-0003-4137-8790Papers by this author
worksTreatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
2017 · Journal of Clinical Oncology · 142 citations
Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial
2020 · Clinical Cancer Research · 113 citations
https://doi.org/10.1158/1078-0432.ccr-20-0844
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
2019 · BMC Medicine · 35 citations
https://doi.org/10.1186/s12916-018-1233-1
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: PALMIRA Trial
2025 · Journal of Clinical Oncology · 10 citations
https://doi.org/10.1200/jco-24-01865
Clinical Trial: Safety and Efficacy of a Novel Oesophageal Delivery System for Topical Corticosteroids Versus Placebo in the Treatment of Eosinophilic Oesophagitis
2024 · Alimentary Pharmacology & Therapeutics · 6 citations
https://doi.org/10.1111/apt.18443
Factors Associated with the Selection of First-line Bevacizumab plus Chemotherapy and Clinical Response in HER2-negative Metastatic Breast Cancer: ONCOSUR AVALOX Study.
2015 · PubMed · 3 citations
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat